Definitive results: IL-2 does not benefit HIV-infected patients. Interleukin-2 improves CD4-cell recovery in patients on antiretroviral therapy, but that benefit does not translate into lower risks for disease or death.

Abstract

For years, researchers have tried to find ways to incorporate interleukin (IL)-2 into HIV management, given its positive effects on CD4-cell counts. However, two large trials this year — SILCAAT and ESPRIT — demonstrated that those positive effects do not translate into …